- Home
- AGL vs KMDA Comparison
AGL vs KMDA Comparison
Compare AGL & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGL
- KMDA
- Stock Information
- Founded
- AGL 2016
- KMDA 1990
- Country
- AGL United States
- KMDA Israel
- Employees
- AGL N/A
- KMDA N/A
- Industry
- AGL Managed Health Care
- KMDA Biotechnology: Pharmaceutical Preparations
- Sector
- AGL Health Care
- KMDA Health Care
- Exchange
- AGL Nasdaq
- KMDA Nasdaq
- Market Cap
- AGL 401.9M
- KMDA 398.5M
- IPO Year
- AGL 2021
- KMDA N/A
- Fundamental
- Price
- AGL $0.86
- KMDA $6.92
- Analyst Decision
- AGL Hold
- KMDA Strong Buy
- Analyst Count
- AGL 20
- KMDA 2
- Target Price
- AGL $2.75
- KMDA $13.00
- AVG Volume (30 Days)
- AGL 6.3M
- KMDA 78.9K
- Earning Date
- AGL 11-04-2025
- KMDA 11-12-2025
- Dividend Yield
- AGL N/A
- KMDA 2.89%
- EPS Growth
- AGL N/A
- KMDA 27.97
- EPS
- AGL N/A
- KMDA 0.32
- Revenue
- AGL $5,901,182,000.00
- KMDA $169,517,000.00
- Revenue This Year
- AGL N/A
- KMDA $14.49
- Revenue Next Year
- AGL $5.76
- KMDA $10.12
- P/E Ratio
- AGL N/A
- KMDA $21.22
- Revenue Growth
- AGL 11.76
- KMDA 9.67
- 52 Week Low
- AGL $0.71
- KMDA $5.45
- 52 Week High
- AGL $6.08
- KMDA $9.16
- Technical
- Relative Strength Index (RSI)
- AGL 35.33
- KMDA 51.34
- Support Level
- AGL $0.93
- KMDA $6.72
- Resistance Level
- AGL $1.03
- KMDA $7.11
- Average True Range (ATR)
- AGL 0.08
- KMDA 0.20
- MACD
- AGL 0.00
- KMDA 0.03
- Stochastic Oscillator
- AGL 5.44
- KMDA 55.56
About AGL agilon health inc.
Agilon Health Inc is transforming healthcare by empowering primary care physicians for the health of the patients. The company enables physicians to create their own Medicare-centric globally capitated line of business. The company derives its revenue from Medical services.
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.